NCT06106802 2026-02-23Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib TreatmentSamsung Medical CenterPhase 2 Recruiting47 enrolled
NCT05541822 2025-05-22To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET DysregulationAbion IncPhase 2 Recruiting178 enrolled
NCT06156527 2023-12-05A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & SmokerNational Cancer Center, KoreaPhase 2 Recruiting120 enrolled